Effects of CPAP on Metabolic Syndrome in Patients With OSA: A Randomized Trial
| Autor: | Sara Q C, Giampá, Sofia F, Furlan, Lunara S, Freitas, Thiago A, Macedo, Adriana, Lebkuchen, Karina H M, Cardozo, Valdemir M, Carvalho, Franco C, Martins, Indira F B, Azam, Valéria, Costa-Hong, Heno F, Lopes, Mariana L, Baptista, Carlos E, Rochitte, Luiz A, Bortolotto, Geraldo, Lorenzi-Filho, Luciano F, Drager |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Chest. 161(5) |
| ISSN: | 1931-3543 0229-5202 |
| Popis: | OSA is associated with metabolic syndrome (MS), but it is unclear whether OSA treatment with CPAP can revert MS.Does OSA treatment with CPAP per se have effects on the MS reversibility and the associated metabolic, adiposity and vascular parameters?The TREATOSA-MS trial is a randomized placebo-controlled trial that enrolled adult patients with a recent diagnosis of MS and moderate or severe OSA (apnea-hypopnea index [AHI], ≥ 15 events/h) to undergo therapeutic CPAP or nasal dilator strips (placebo group) for 6 months. Before and after each intervention, we measured anthropometric variables, BP, glucose, and lipid profile. To control potential-related mechanisms and consequences, we also measured adiposity biomarkers (leptin and adiponectin), body composition, food intake, physical activity, subcutaneous and abdominal fat (visceral and hepatic fat), and endothelial function.One hundred patients (79% men; mean age, 48 ± 9 years; BMI, 33 ± 4 kg/mDespite the higher rate of MS reversibility after CPAP therapy as compared with placebo, most patients retained this diagnosis. The lack of significant or relevant effects on adiposity biomarkers and depots supports the modest role of OSA in modulating MS.ClinicalTrials.gov; No.: NCT02295202; URL: www.gov. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|